{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:05Z","timestamp":1790776565180,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113858"],"award-info":[{"award-number":["70113858"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Ministry of Research and Education","award":["01ZZ1802"],"award-info":[{"award-number":["01ZZ1802"]}]},{"name":"German Ministry of Research and Education","award":["01ZZ3222E"],"award-info":[{"award-number":["01ZZ3222E"]}]},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11523-024-01044-1","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:02:24Z","timestamp":1709132544000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data"],"prefix":"10.1007","volume":"19","author":[{"given":"Alexander","family":"Olkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Katrin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Rauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Puchas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrill","family":"Wehling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pfeiffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Michl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-4204","authenticated-orcid":false,"given":"Michael T.","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"10272","key":"1044_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"6","key":"1044_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000453013","volume":"32","author":"MM Kirstein","year":"2016","unstructured":"Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016;32(6):395\u2013400.","journal-title":"Visc Med."},{"issue":"10","key":"1044_CR3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00595-006-3276-8","volume":"36","author":"W-S Lee","year":"2006","unstructured":"Lee W-S, Lee K-W, Heo J-S, Kim S-J, Choi S-H, Kim Y-I, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36(10):892\u20137.","journal-title":"Surg Today"},{"issue":"9","key":"1044_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"14","key":"1044_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"4","key":"1044_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469\u201374.","journal-title":"Br J Cancer"},{"issue":"6","key":"1044_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u201332.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"S1462","DOI":"10.1016\/j.annonc.2022.10.114","volume":"33","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33:S1462\u20133.","journal-title":"Ann Oncol"},{"issue":"6","key":"1044_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","volume":"20","author":"TF Greten","year":"2023","unstructured":"Greten TF, Schwabe R, Bardeesy N, Ma L, Goyal L, Kelley RK, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(6):349\u201365.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1044_CR10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/vaccines11061062","volume":"11","author":"E Manthopoulou","year":"2023","unstructured":"Manthopoulou E, Ramai D, Dhar J, Samanta J, Ioannou A, Lusina E, et al. Cholangiocarcinoma in the era of immunotherapy. Vaccines (Basel). 2023;11(6):1062.","journal-title":"Vaccines (Basel)."},{"issue":"10","key":"1044_CR11","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116\u201335.","journal-title":"Cancer Discov"},{"issue":"12","key":"1044_CR12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"W Chan-On","year":"2013","unstructured":"Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013;45(12):1474\u20138.","journal-title":"Nat Genet"},{"issue":"4","key":"1044_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/hep.31110","volume":"72","author":"B Goeppert","year":"2020","unstructured":"Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, et al. Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities. Hepatology. 2020;72(4):1253\u201366.","journal-title":"Hepatology"},{"issue":"6","key":"1044_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","volume":"3","author":"YM Wu","year":"2013","unstructured":"Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636\u201347.","journal-title":"Cancer Discov"},{"issue":"9","key":"1044_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003\u201310.","journal-title":"Nat Genet"},{"issue":"5","key":"1044_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1044_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21(2):271\u201382.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1044_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdy539","volume":"30","author":"DS Hong","year":"2019","unstructured":"Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30(2):325\u201331.","journal-title":"Ann Oncol"},{"issue":"3","key":"1044_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"1044_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","volume":"120","author":"B Goeppert","year":"2019","unstructured":"Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, et al. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. Br J Cancer. 2019;120(1):109\u201314.","journal-title":"Br J Cancer"},{"issue":"1","key":"1044_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1044_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13244-020-00907-1","volume":"11","author":"TF Weber","year":"2020","unstructured":"Weber TF, Spurny M, Hasse FC, Sedlaczek O, Haag GM, Springfeld C, et al. Improving radiologic communication in oncology: a single-centre experience with structured reporting for cancer patients. Insights Imaging. 2020;11(1):106.","journal-title":"Insights Imaging"},{"issue":"9","key":"1044_CR23","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","volume":"127","author":"A Tomczak","year":"2022","unstructured":"Tomczak A, Springfeld C, Dill MT, Chang DH, Kazdal D, Wagner U, et al. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice. Br J Cancer. 2022;127(9):1701\u20138.","journal-title":"Br J Cancer"},{"issue":"10391","key":"1044_CR24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"8","key":"1044_CR25","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803\u201312.","journal-title":"Liver Int"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01044-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01044-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T10:51:43Z","timestamp":1711363903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01044-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01044-1","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"5 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. A.T. is supported by the German Ministry of Research and Education (01ZZ1802, 01ZZ3222E). M.T.D. is supported by a Max Eder funding grant (70113858) of the German Cancer Aid.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"P. Michl receives speakers honorary by AstraZeneca. Alexander Olkus, Aurelie Tomczak, Anne Katrin Berger, Conrad Rauber, Philip Puchas, Cyrill Wehling, Thomas Longerich, Arianeb Mehrabi, De-Hua Chang, Jakob Liermann, Sophia Sch\u00e4fer, Jan Pfeiffenberger, Dirk J\u00e4ger, Christoph Springfeld and Michael T. Dill declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The LCCH registry study was approved by the local ethics committee of the Heidelberg University Hospital (S-693\/2019). Informed consent was obtained from all prospectively enrolled patients. The study was performed in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate:"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Relevant genomic data are provided as Supplementary Material. Additional data are available upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A.O. and M.T.D. conceived and designed the study. A.O., A.T., T.L. and M.T.D. analysed the data. A.B., T.L., C.S., P.P., C.R., C.W., M.T.D., A.M., D.H.C., J.L., J.P., D.J. and P.M. participated in interdisciplinary tumour board decisions, supervised clinical annotations and provided critical data interpretation. S.S. supervised the clinical cancer registry and provided intellectual input. A.O. and M.T.D. wrote the manuscript. A.B., C.S. and A.T. provided substantial editorial work to the manuscript. All authors have read and provided comments on the manuscript. All authors approved the manuscript and gave their consent for submission and publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}